Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter to the Editor re: Sealing Properties of Close-Fitting Masks Worn Over Facial Hair.

Aerospace medicine and human performance·2026
Same author

Characteristics, all-cause healthcare resource utilisation, and costs among high-risk adults with long COVID during Omicron predominance, 2022-2023: a retrospective cohort study using UK primary care data.

BMC health services research·2026
Same author

Real-World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug-Based Cohort Study.

International journal of rheumatic diseases·2026
Same author

Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study.

Rheumatology and therapy·2026
Same author

Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United States.

Arthritis research & therapy·2026
Same author

Hip Fractures Sustained Through Inpatient Falls Are Associated With Lower Rates of Fascia Iliaca Block Administration and Higher Opiate Requirements: A Single-Centre Experience.

Cureus·2026
Same journal

Predictor-Assisted Nonparametric Graphical Models With Multivariate Error-Prone Data.

Statistics in medicine·2026
Same journal

Optimizing Treatment Decision Estimation for Right-Censored Survival Data Through Parameter Transfer Learning.

Statistics in medicine·2026
Same journal

Latent Class Log-Linear Models for Estimating Diagnostic Test Accuracy Without a Gold Standard: A Simulation Study.

Statistics in medicine·2026
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation

Published on: September 4, 2017

A case study of model-based Bayesian dose response estimation.

Huaming Tan1, David Gruben, Jonathan French

  • 1Pfizer Inc., 50 Pequot Ave, New London, CT 06320, USA. huaming.tan@pfizer.com

Statistics in Medicine
|June 30, 2011
PubMed
Summary
This summary is machine-generated.

A Bayesian nonlinear longitudinal Emax model improved rheumatoid arthritis treatment dose-response characterization. This pharmacometric approach enhanced precision and guided future dosing decisions for chronic disease drug development.

More Related Videos

Evaluating Toxicity of Chemicals using a Zebrafish Vibration Startle Response Screening System
06:25

Evaluating Toxicity of Chemicals using a Zebrafish Vibration Startle Response Screening System

Published on: January 12, 2024

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

Related Experiment Videos

Last Updated: May 31, 2026

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation

Published on: September 4, 2017

Evaluating Toxicity of Chemicals using a Zebrafish Vibration Startle Response Screening System
06:25

Evaluating Toxicity of Chemicals using a Zebrafish Vibration Startle Response Screening System

Published on: January 12, 2024

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

Area of Science:

  • Pharmacometrics
  • Longitudinal Data Analysis
  • Bayesian Modeling

Background:

  • Characterizing dose-response relationships is crucial for drug development, especially for chronic diseases like rheumatoid arthritis.
  • Traditional methods may lack precision when combining data from multiple studies or extrapolating across time points.

Purpose of the Study:

  • To apply a Bayesian nonlinear longitudinal Emax model for a binary endpoint to characterize the dose-response relationship of a new rheumatoid arthritis treatment.
  • To demonstrate the utility of substantive parametric models in guiding dose selection for future clinical studies.

Main Methods:

  • Utilized a Bayesian nonlinear longitudinal Emax model with prespecified parametric functions for dose and time dependence.
  • Combined data from two studies conducted at different doses and times.
  • Compared results with a logistic regression model applied at a single time point.
  • Described the specification of an informative prior distribution.

Main Results:

  • The longitudinal model effectively combined data from different doses and study time points, improving precision compared to single time-point analysis.
  • Identified optimal doses likely to achieve targeted effects in confirmatory trials.
  • The model facilitated dose selection for future Phase 2 and extrapolation to Phase 3 studies.

Conclusions:

  • Bayesian nonlinear longitudinal Emax models offer a robust framework for dose-response characterization in drug development.
  • These models enhance precision and provide valuable guidance for optimizing dosing strategies in chronic diseases.
  • Challenges in prior distribution specification remain but are surmountable for advancing Bayesian applications.